Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Delcath Systems, Inc.

Market Cap 378M 327M 300M 282M 526M 35.99B 534M 3.57B 1.39B 17.4B 1.42B 1.39B 60.53B P/E ratio 2026 *
-18.3x
P/E ratio 2027 * -22.5x
Enterprise value 378M 327M 300M 282M 526M 35.99B 534M 3.57B 1.39B 17.4B 1.42B 1.39B 60.53B EV / Sales 2026 *
3.64x
EV / Sales 2027 * 2.82x
Free-Float
91.87%
Yield 2026 *
-
Yield 2027 * -
1 day+2.53%
1 week+3.21%
Current month+1.48%
1 month-4.70%
3 months+20.48%
6 months+13.49%
Current year+8.32%
1 week 10.2
Extreme 10.2
11.38
1 month 10.2
Extreme 10.2
11.72
Current year 8.48
Extreme 8.485
12.27
1 year 8.12
Extreme 8.12
16.56
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
1,000,000
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Compliance Officer 56 25/01/2022
Director TitleAgeSince
Director/Board Member 62 01/10/2020
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Date Insider Type Main position Quantity % Market Cap.
05-13Free

Chairman

22,500 0.0646%
05-13Free

Director

22,500 0.0646%
05-13Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
+2.53%+3.21%-33.21%+56.29% 378M
+1.34%+2.02%-12.80%-27.88% 19.1B
+0.19%+0.78%-20.25%-14.00% 15.43B
+2.18%+6.10%-61.92%-57.14% 4.65B
+0.39%-2.45% - - 3.81B
-0.28%0.00%-20.59%-13.32% 1.78B
+1.86%-0.42%+24.41%-9.45% 1.53B
-2.78%-7.99%-43.31%-63.33% 1.15B
+1.90%-0.17%+40.91%+107.39% 690M
-15.64%-30.43% - - 495M
Average -0.83%-3.75%-15.84%-2.68% 4.9B
Weighted average by Cap. +0.68%+0.21%-19.64%-23.03%

Financials

2026 *2027 *
Net sales 104M 89.95M 82.54M 77.65M 145M 9.9B 147M 981M 382M 4.79B 390M 382M 16.65B 134M 116M 106M 100M 187M 12.77B 190M 1.27B 493M 6.18B 503M 492M 21.48B
Net income -21.94M -19M -17.43M -16.4M -30.55M -2.09B -31.03M -207M -80.64M -1.01B -82.38M -80.58M -3.52B -18.01M -15.59M -14.31M -13.46M -25.07M -1.72B -25.46M -170M -66.19M -830M -67.61M -66.14M -2.89B
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
08/06/26 10.94 $ +2.53% 1,200,329
05/06/26 10.67 $ -1.11% 588,208
04/06/26 10.79 $ +4.45% 415,438
03/06/26 10.33 $ -1.90% 400,257
02/06/26 10.53 $ -0.66% 531,249
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.94USD
Average target price
20.79USD
Spread / Average Target
+90.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW